Ian Fearon is an independent consultant with expertise in regulatory and scientific aspects of nicotine and tobacco products. His consulting work encompasses clinical and behavioural studies of tobacco and nicotine products for regulatory submissions in the US and Europe, and he has a wealth of experience of both consumer goods and medicinal licensing submissions.  His 15 years working in the Tobacco Harm Reduction arena has included roles as Senior Director of Clinical and Regulatory Affairs EMEA with JUUL Labs, Director of Tobacco Research with Celerion, and Principal Scientist and Head of Clinical Research at British American Tobacco. 

Scott J. Leischow, Ph.D. joined the Mayo Clinic in 2012, where he leads the Research on Health Equity and Community Health (REACH) Program at Mayo Clinic Arizona, and co-leads Cancer Prevention and Control within the Mayo Clinic Cancer Center. He was formerly University of Arizona and also served as Senior Advisor for Tobacco Policy in the US Department of Health and Human Services and Chief of the Tobacco Control Research Branch at the National Cancer Institute of NIH. Dr. Leischow completed his doctorate in Health Education from the University of Maryland, and a postdoctoral fellowship in Behavioral Pharmacology from Johns Hopkins University. Dr. Leischow has received several awards, including the NIH Director’s Award. Most of Dr. Leischow’s research and publications focus on pharmacologic and behavioral treatments for tobacco dependence, along with systems and network approaches to public health. Dr. Leischow is past President of the Society for Research on Nicotine and Tobacco (SRNT).

Martin Cullip is a former company director and International Fellow of the Taxpayers Protection Alliance, who has written and blogged on free market and lifestyle consumer issues for over a decade. As a user of e-cigarettes and other safer nicotine products, he is a particularly passionate consumer advocate for all forms of tobacco harm reduction and has a keen interest in the rapidly-evolving nicotine market and the politics surrounding it. Martin is a former Chair of UK educational charity, The New Nicotine Alliance, and has taken part in parliamentary evidence sessions and consumer, industry, and political events on the subject domestically and internationally.

Jasjit S. Ahluwalia is a physician and public health scientist at Brown University’s Schools of Public Health and Medicine. He has been in academic medicine since 1992. His primary research areas are smoking cessation and nicotine addiction in African American smokers for which he has secured more than $120 million as a PI, Co-PI and Co-Investigator. He has been continuously funded by the National Institutes of Health for 28 years and has published more than 375 manuscripts. Ahluwalia has served on the U.S. government’s National Advisory Council on Minority Health and Health Disparities, on the SRNT board of directors and recently completed a 3-year term on the federal government’s Interagency Committee on Smoking and Health chaired by the U.S. Surgeon General.

Brian Quigley has over twenty-five years of Marketing, Regulatory, Operations and Business Leadership experience for public companies, private equity backed businesses and venture backed businesses.

Brian is currently Chief Executive Officer for Qnovia, Inc. a U.S. based venture backed pharmaceutical company, focused on inhaled drug delivery across a host of indication areas. Qnovia's is currently engaged with the FDA CEDR to pursue a combination product application for its lead asset (QN-01) to be the first inhalable prescription smoking cessation therapy. Brian joined Qnovia in July 2020 as Chief Operating Officer. Prior to Qnovia, Brian spent 16 years at Altria Group, with his last 7 years as President & CEO for Altria’s Smokeless and Innovative Products/Vapor Businesses.

Brian has also been an active venture investor, and is on the Board of Mustgrow Biologics, Belle Isle Craft Spirits and the Virginia Foundation of Independent Colleges.

Brian lives in Richmond,VA with his wife Amy and three sons.

Mark Dickinson owns Clarityse Ltd, an independent strategic marketing consultancy with extensive experience across the OTC Medicines and Vaping sectors. Mark spent 17 years at GSK in various Global, EMEA and UK senior marketing roles, including 8 years directing their smoking control brands - through the period in which NRT products were made reimbursable in the UK and the prescription segment developed. He has worked extensively at the interface of marketing, regulatory affairs and public policy. He owned a vape shop and more recently has been helping companies with the commercial aspects of bringing a medicinal vape product to market.